Santen Pharmaceutical Toekomstige groei
Future criteriumcontroles 2/6
Santen Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 11.5% en 0.03% per jaar. De winst per aandeel zal naar verwachting groeien met 12.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 11.7% zijn.
Belangrijke informatie
11.5%
Groei van de winst
12.4%
Groei van de winst per aandeel
| Pharmaceuticals winstgroei | 11.7% |
| Inkomstengroei | 0.03% |
| Toekomstig rendement op eigen vermogen | 11.7% |
| Dekking van analisten | Good |
| Laatst bijgewerkt | 14 Nov 2024 |
Recente toekomstige groei-updates
Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11
Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Recent updates
Santen Pharmaceutical (TSE:4536) Is Posting Promising Earnings But The Good News Doesn’t Stop There
Nov 18Santen Pharmaceutical Co., Ltd. Just Beat EPS By 5.5%: Here's What Analysts Think Will Happen Next
Nov 11Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Share Price Could Signal Some Risk
Oct 14Calculating The Intrinsic Value Of Santen Pharmaceutical Co., Ltd. (TSE:4536)
Aug 31Santen Pharmaceutical Co., Ltd. Just Recorded A 25% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 08Unpleasant Surprises Could Be In Store For Santen Pharmaceutical Co., Ltd.'s (TSE:4536) Shares
Jun 25Santen Pharmaceutical Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models
May 11Is There An Opportunity With Santen Pharmaceutical Co., Ltd.'s (TSE:4536) 34% Undervaluation?
May 08Winst- en omzetgroeiprognoses
| Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
|---|---|---|---|---|---|
| 3/31/2027 | 300,156 | 39,788 | 43,836 | 56,925 | 9 |
| 3/31/2026 | 295,178 | 37,142 | 45,336 | 59,250 | 10 |
| 3/31/2025 | 300,827 | 35,034 | 42,769 | 48,000 | 9 |
| 9/30/2024 | 302,563 | 26,124 | 63,311 | 73,225 | N/A |
| 6/30/2024 | 304,347 | 26,853 | 74,303 | 82,244 | N/A |
| 3/31/2024 | 301,965 | 26,634 | 62,758 | 72,649 | N/A |
| 12/31/2023 | 302,084 | 27,714 | 58,150 | 68,107 | N/A |
| 9/30/2023 | 295,928 | 26,364 | 33,466 | 46,547 | N/A |
| 6/30/2023 | 285,893 | -11,205 | 15,996 | 37,272 | N/A |
| 3/31/2023 | 279,037 | -14,955 | 12,559 | 37,147 | N/A |
| 12/31/2022 | 270,242 | -8,195 | 7,347 | 43,335 | N/A |
| 9/30/2022 | 266,413 | -9,133 | 17 | 37,279 | N/A |
| 6/30/2022 | 266,804 | 26,533 | 8,572 | 45,922 | N/A |
| 3/31/2022 | 266,257 | 27,212 | 10,202 | 46,043 | N/A |
| 12/31/2021 | 263,620 | 5,056 | 22,775 | 46,172 | N/A |
| 9/30/2021 | 259,459 | 7,319 | 22,195 | 47,476 | N/A |
| 6/30/2021 | 257,028 | 7,978 | 13,713 | 33,903 | N/A |
| 3/31/2021 | 249,605 | 6,826 | 15,004 | 38,808 | N/A |
| 12/31/2020 | 241,015 | 24,430 | 13,214 | 36,409 | N/A |
| 9/30/2020 | 241,685 | 24,279 | 16,958 | 34,787 | N/A |
| 6/30/2020 | 239,982 | 23,404 | 26,917 | 42,393 | N/A |
| 3/31/2020 | 241,555 | 23,616 | 30,719 | 39,947 | N/A |
| 12/31/2019 | 243,142 | 28,876 | 28,909 | 37,562 | N/A |
| 9/30/2019 | 238,457 | 30,721 | 30,088 | 39,233 | N/A |
| 6/30/2019 | 236,679 | 31,498 | 32,229 | 41,100 | N/A |
| 3/31/2019 | 234,026 | 31,953 | 24,561 | 32,894 | N/A |
| 12/31/2018 | 229,560 | 31,291 | 26,462 | 36,492 | N/A |
| 9/30/2018 | 228,512 | 34,370 | 28,786 | 38,360 | N/A |
| 6/30/2018 | 225,477 | 33,083 | N/A | 34,561 | N/A |
| 3/31/2018 | 224,942 | 35,247 | N/A | 42,843 | N/A |
| 12/31/2017 | 217,021 | 30,580 | N/A | 39,581 | N/A |
| 9/30/2017 | 212,041 | 25,717 | N/A | 37,624 | N/A |
| 6/30/2017 | 205,038 | 24,756 | N/A | 30,180 | N/A |
| 3/31/2017 | 199,096 | 23,061 | N/A | 10,843 | N/A |
| 12/31/2016 | 196,754 | 23,299 | N/A | 4,869 | N/A |
| 9/30/2016 | 195,247 | 22,317 | N/A | 5,091 | N/A |
| 6/30/2016 | 197,322 | 53,155 | N/A | 8,601 | N/A |
| 3/31/2016 | 195,291 | 53,373 | N/A | 22,525 | N/A |
| 12/31/2015 | 194,193 | 57,729 | N/A | 29,919 | N/A |
| 9/30/2015 | 187,779 | 58,590 | N/A | 34,513 | N/A |
| 6/30/2015 | 176,124 | 27,842 | N/A | 30,263 | N/A |
| 3/31/2015 | 161,831 | 24,032 | N/A | 25,386 | N/A |
| 12/31/2014 | 156,559 | 17,923 | N/A | 23,350 | N/A |
| 9/30/2014 | 151,325 | 17,214 | N/A | 17,923 | N/A |
| 6/30/2014 | 148,031 | 15,278 | N/A | 19,086 | N/A |
| 3/31/2014 | 148,663 | 17,109 | N/A | 25,958 | N/A |
| 12/31/2013 | 139,587 | 17,760 | N/A | 19,774 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei 4536 ( 11.5% per jaar) ligt boven de spaarquote ( 0.3% ).
Winst versus markt: De winst van 4536 ( 11.5% per jaar) zal naar verwachting sneller groeien dan de JP markt ( 7.9% per jaar).
Hoge groeiwinsten: De winst van 4536 zal naar verwachting groeien, maar niet aanzienlijk.
Omzet versus markt: De omzet van 4536 ( 0.03% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 4.2% per jaar).
Hoge groei-inkomsten: De omzet van 4536 ( 0.03% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen 4536 zal naar verwachting over 3 jaar laag zijn ( 11.7 %).